VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial.
Duncan J. Stewart,Michael J.B. Kutryk,David Fitchett,Michael R. Freeman,Nancy Camack,Yinghua Su,Anthony Della Siega,Luc Bilodeau,Jeffrey R. Burton,Guy Proulx,Sam Radhakrishnan +10 more
TLDR
There was no difference between the VEGF-treated and the placebo groups in the primary end point of change in myocardial perfusion from baseline to 3 or 6 months, assessed by single photon emission tomography (SPECT) imaging, although a significant reduction in the ischemic area was seen in both groups.About:
This article is published in Molecular Therapy.The article was published on 2009-06-01 and is currently open access. It has received 238 citations till now. The article focuses on the topics: Revascularization & Myocardial perfusion imaging.read more
Citations
More filters
Journal ArticleDOI
VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart
Jun-Ming Tang,Jia-Ning Wang,Lei Zhang,Fei Zheng,Jian-Ye Yang,Xia Kong,Linyun Guo,Long Chen,Yong-Zhang Huang,Yu Wan,Shi-You Chen +10 more
TL;DR: Functional studies showed that (VEGF)MSC transplantation stimulated extensive angiomyogenesis in infarcted hearts as indicated by the expression of cardiac troponin T, CD31, and von Willebrand factor and improved the left ventricular performance, whereas blockade of SDF-1α or its receptor by RNAi or antagonist significantly diminished the beneficial effects of (VE GF) MSC.
Journal ArticleDOI
VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond.
Mauro Giacca,Serena Zacchigna +1 more
TL;DR: The VEGF-based therapies that have already reached clinical experimentation are critically reviewed and the pleiotropic activities of V EGF factors that might create new opportunities for therapeutic application are highlighted.
Journal ArticleDOI
Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges
TL;DR: Administration of mesenchymal stem cells to diseased hearts improves cardiac function and reduces scar size and demonstrates the potential of stem cell therapy, but the goal of full cardiac recovery has yet to be realized in either preclinical or clinical studies.
Journal ArticleDOI
Cell sheet approach for tissue engineering and regenerative medicine.
TL;DR: The integration of stem cell biology and cell sheet technology with sufficient vascularization opens possibilities for fabrication of human three-dimensional vascularized dense and intact tissue grafts for regenerative medicine to parenchymal organs.
Journal ArticleDOI
Vascular endothelial growth factor in heart failure
TL;DR: The biological characterization of VEGF is outlined, and the evidence for its potential therapeutic application is examined, including the novel concept of V EGF as adjuvant therapy to stem cell transplantation, in patients with heart failure.
References
More filters
Journal ArticleDOI
Angiogenesis as a therapeutic target
TL;DR: Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Journal ArticleDOI
VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells
Takayuki Asahara,Tomono Takahashi,Haruchika Masuda,Christoph Kalka,Donghui Chen,Hideki Iwaguro,Yoko Inai,Marcy Silver,Jeffrey M. Isner +8 more
TL;DR: A novel role is established for VEGF in postnatal neovascularization which complements its known impact on angiogenesis and is based on data from animal models and human subjects.
Journal ArticleDOI
Molecular and biological properties of vascular endothelial growth factor.
TL;DR: Current evidence indicates that VEGF is essential for embryonic vasculogenesis and angiogenesis, and both therapeuticAngiogenesis using recombinant V EGF or VEGFs gene transfer and inhibition of VEGf-mediated pathological angiogenic are being pursued.
Journal ArticleDOI
The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Timothy D. Henry,Brian H. Annex,George R. McKendall,Michael Azrin,John J. Lopez,Frank J. Giordano,Prediman K. Shah,James T. Willerson,Raymond L. Benza,Daniel S. Berman,C. Michael Gibson,Alex Bajamonde,Amy Chen Rundle,J. T. Fine,Edward R. McCluskey +14 more
TL;DR: The VIVA (Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis) trial as discussed by the authors was designed to evaluate the safety and efficacy of intracoronary and intravenous infusions of rhVEGF.
Journal ArticleDOI
Angiogenesis Inhibitors Endostatin or TNP-470 Reduce Intimal Neovascularization and Plaque Growth in Apolipoprotein E–Deficient Mice
Karen S. Moulton,Eric A. Heller,Moritz A. Konerding,Evelyn Flynn,Wulf Palinski,Judah Folkman +5 more
TL;DR: Prolonged treatment with either angiogenesis inhibitor reduced plaque growth and intimal neovascularization in apoE -/- mice, and these results suggest that intimal nvascularization may promote plaque development.